SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Amazon.com, Inc. is a multinational technology company, which engages in the provision of online retail shopping services. It operates through the following segments: North America, International, and Amazon Web Services (AWS). The North America segment offers retail sale of consumer products, including from sellers, advertising, and subscriptions services through North America-focused online and physical stores. The International segment focuses on retail sale of consumer products, including sellers, advertising, and subscription services through internationally focused online stores. The AWS segment is composed of global sales of computers, storage, databases, and other services for start-ups, enterprises, government agencies, and academic institutions. The company was founded by Jeffrey P. Bezos in July 1994 and is headquartered in Seattle, WA.

Amazon.com Inc.

Amazon.com Inc

Morgan Stanleys designation of Amazon as a top pick, alongside optimism about AWS growth and AI initiatives such as Trainium, is driving attention. Many traders welcomed the sharp move, while others questioned the rally or discussed taking profits and looking for a pullback.

Disc Medicine, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery, development, and commercialization of treatments for hematologic diseases. It assembles a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis. The company was founded in October 2017 and is headquartered in Watertown, MA.

Disc Medicine Inc

Disc Medicine is surging after bitopertin met all primary and secondary endpoints in the Phase 3 APOLLO trial for erythropoietic protoporphyria, strengthening the companys path toward an FDA resubmission. Traders are broadly bullish and debating a possible short squeeze, while some cite dizziness concerns and potential profit-taking.

Sea Ltd. is an internet and mobile platform company, which engages in the provision of online gaming services. It operates through the following segments: Digital Entertainment, E-Commerce, and Digital Financial Services. The Digital Entertainment segment offers and develops mobile and PC online games. The E-Commerce segment manages a third-party marketplace through the Shopee mobile app and websites that connect buyers and sellers. The Digital Financial Services segment includes a variety of payment services and loans to individuals and businesses through SeaMoney. Sea was founded by Xiao Dong Li, Gang Ye, and Jing Ye Chen on May 8, 2009 and is headquartered in Singapore.

Sea Ltd - ADR

Sea shares are drawing attention after a sharp slide and technical breakdown, with traders repeatedly pointing to insider share sales as added selling pressure. Some view the sales as planned and the decline as disconnected from the companys growth, while others worry about management confidence and cite broader Southeast Asian market and oil-related risks.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

IBRX is drawing attention for a sharp selloff despite the FDAs expanded ANKTIVA approval for papillary bladder cancer and encouraging long-term trial data. Traders debate whether the decline reflects sell-the-news profit-taking and broader biotech weakness, while others blame options-related pressure or short selling; concerns about revenue growth and future dilution also surface.

Cleveland-Cliffs, Inc. is a flat-rolled steel company, which engages in provision of iron ore pellets to the North American steel industry. It focuses on the production of metallic and coke, iron making, steelmaking, rolling and finishing, and downstream tubular components, stamping, and tooling. It operates through the Steelmaking and Other Businesses segments. The company was founded in 1847 and is headquartered in Cleveland, OH.

Cleveland-Cliffs Inc

Cleveland-Cliffs stronger-than-guided third-quarter results and upbeat 2027 EBITDA outlook have driven a sharp rally, with traders also pointing to short-covering and higher steel prices. The reaction is divided: bulls see room for continued gains, while skeptics warn the rally could fade and question whether the outlook can overcome the companys debt concerns.

CoreWeave, Inc. engages in the powers of the creation and delivery of the intelligence that drives innovation. It offers a solution used by organizations of all sizes that require sophisticated AI computing, from the largest of enterprises to small, well-funded start-ups. The company was founded by Michael Intrator, Brian Venturo, Peter Salanki, and Brannin McBee on September 21, 2017 and is headquartered in Livingston, NJ.

CoreWeave Inc. - Ordinary Shares - Class A

CoreWeave Inc

Goldman Sachs upgrade of CoreWeave to Buy after a sharp selloff sparked a rebound attempt, but traders debated whether the call could overcome persistent selling. The main divide is between optimism about AI-compute demand and contracted backlog, and concern that heavy debt and financing costs could threaten the business.

Cerebras Systems, Inc. engages in the designing and provision of processors for artificial intelligence (AI) training and inference. Its products include inference, Wafer Scale Engine, AI supercomputers, AI model services, cloud, systems, and processors. The company was founded by Sean Lie, Andrew D. Feldman, Gary Lauterbach, Michael James, and Jean Philippe Fricker in 2015 and is headquartered in Sunnyvale, CA.

Cerebras Systems Inc - Ordinary Shares - Class A

Cerebras Systems Inc

Cerebras is drawing attention after a steep post-IPO selloff, with traders citing share-unlock and insider-selling pressure, valuation and growth concerns, and broader weakness in AI and semiconductor stocks. Bulls are buying the dip and arguing the decline is overdone, while bears warn that selling could continue.

Almonty Industries, Inc. engages in the mining, processing, and shipment of tungsten concentrates. Its projects include Almonty Korea Tungsten, Panasquiera mine, Gentung, Almonty Korea Moly, Los Santos mine, and Valtreixal. The company was founded on September 28, 2009 and is headquartered in Dillon, MT.

Almonty Industries Inc

Almonty is drawing attention after a sharp selloff around its investor day, with traders divided over CEO Lewis Blacks presentation: some found the remarks positive, while others read his delivery as a sign of undisclosed problems. Bullish holders continue to cite the Sangdong production ramp and tungsten-supply outlook, while skeptics are focused on execution and the lack of clear reassurance.

X-Energy, Inc. engages in the development of advanced small modular nuclear reactors and fuel technology for clean energy generation. Its solutions include Xe-100 and TRISO-X. The company was founded by Kam Ghaffarian and Eben Mulder in 2009 and is headquartered in Rockville, MD.

X-Energy Inc. - Ordinary Shares- Class A

X-Energy Inc

AEP and X-energy are evaluating a 960-MW small modular reactor project in Indiana, with Amazon backing development and a proposed long-term power purchase agreement; traders view it as a potential expansion of X-energys data-center power opportunity, though the project remains at the evaluation stage. Sentiment is split between long-term optimism about nuclear demand and frustration over XEs sharp decline, volatility, and lengthy path to commercial deployment.

Sunrun, Inc. engages in the design, development, installation, sale, ownership, and maintenance of residential solar energy systems. It sells solar service offerings and installs solar energy systems for homeowners. Customers can access its products through three channels: direct-to-consumer, solar partnerships, and strategic partnerships. The company was founded by Edward Harris Fenster, Robert Nat Kreamer, and Lynn Michelle Jurich in January 2007 and is headquartered in San Francisco, CA.

Sunrun Inc

Sunruns continued share-price decline and heavy short interest dominate the discussion, with traders debating whether rate-sensitive solar-sector pressures and weak guidance outweigh the companys storage, virtual-power-plant, and AI data-center potential. Some see a possible short squeeze or recovery, while others expect further downside.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

12 Health Care Stocks Moving In Friday's Intraday Session

Gainers

Quoin Pharmaceuticals (NASDAQ:QNRX) shares rose 24.6% to $6.42 during Friday's regular session. The company's market cap stands at $10.3 million.
Aethlon Medical (NASDAQ:AEMD) shares moved upwards byread more...

Biotech Bombshells and AI Power Plays: The Stocks Suddenly Turning Heads

Today’s market action is being driven by hard catalysts. Quoin Pharmaceuticals (NASDAQ:QNRX) has fresh interim clinical data; NeOnc Technologies Holdings (NASDAQ:NTHI) has moved its NEO100 story toward an FDA registration discussion; FingerMotion (NASDAQ:FNGR) is attempting a major strategic pivot toward AI infrastructure; and Solstice Advanced Materials (NASDAQ: SOLS) has replaced a transformative merger with a $500 million buyback and an independent-growth narrative. Meanwhile, Gap (NYSE: GAP) is demonstrating that a mature consumer company can still generate sharp divergence between individual brands.

Quoin Pharmaceuticals Stock Surges Friday: What's Happening?

Shares of Quoin Pharmaceuticals are rallying Friday after pre-market updates on positive trial results and a major institutional financing.read more...

12 Health Care Stocks Moving In Friday's Pre-Market Session

Gainers

Quoin Pharmaceuticals (NASDAQ:QNRX) shares rose 41.4% to $7.29 during Friday's pre-market session. The company's market cap stands at $10.3 million.
Aethlon Medical (NASDAQ:AEMD) stock moved upwards byread more...

Quoin’s Netherton Data Turns Heads and Could Make QRX003 Breakout Catalyst

Quoin Pharmaceuticals (NASDAQ:QNRX) delivered the kind of interim clinical signal that can abruptly change the conversation around a small-cap biotech: its investigational QRX003 lotion produced statistically significant improvements in key measures of Netherton Syndrome in the first six patients to complete 12 weeks of treatment. The company says four of six participants, or 66.7%, achieved at least a one-grade improvement on the Investigator Global Assessment, producing a p=0.0087 result that cleared the study’s pre-specified interim alpha of 0.0215.

12 Health Care Stocks Moving In Tuesday's After-Market Session

Gainers

Quoin Pharmaceuticals (NASDAQ:QNRX) shares rose 40.3% to $4.56 during Tuesday's after-market session. The market value of their outstanding shares is at $8.8 million.
Mobile-health Network (NASDAQ:MNDR)read more...

Quoin Pharmaceuticals Garners Buzz After FDA’s Comments On Netherton Syndrome Lead Drug

Equity

The U.S. Food and Drug Administration indicated that a single Phase 3 trial of QRX003 could be enough to support approval in the U.S.

Quoin Pharmaceuticals Gains FDA Alignment, Eyes Streamlined Path to First Netherton Syndrome Treatment

Quoin Pharmaceuticals (NASDAQ:QNRX) reported a key regulatory milestone following a constructive Type C meeting with the U.S. Food and Drug Administration (FDA), potentially accelerating the development path for its lead candidate, QRX003, in the treatment of Netherton Syndrome, a rare and underserved genetic skin disorder.

QNRX Stock Soared A Whopping 39% Today: What’s Driving The Relentless Rally? 

A rapamycin loading concentration of 4% w/w has been achieved for Quoin’s topical formulation, while an even higher concentration of 5% w/w has been formulated in a dermal patch system, the company said.

QNRX Stock Soars 300% After $104.5M Financing Through Private Placement

Quoin said that the purchase agreement also includes an initial upfront funding of $16.5 million and up to an additional $88 million upon the potential cash exercise of accompanying warrants at the election of the investors.

Quoin Pharmaceuticals Ltd. engages in the development of therapeutic products for the treatment of rare and orphan diseases. Its product pipeline includes QRX003, QRX004, QRX007, and QRX008. The company was founded by Michael Myers and Denise Carter on March 5, 2018 and is headquartered in Ashburn, VA.

Quoin Pharmaceuticals Ltd - ADR

Bullish Sentiment

<ul class="summary-bullets"><li>The FDA indicated openness to alternative trial designs such as not using a placebo group for the Phase 3 trial.</li><li>Quoin remains on track to complete patient enrollment for the next phase, it added.</li><li>Last week, the FDA granted Fast Track designation to the company’s QRX003.</li></ul>Shares of Quoin Pharmaceuticals (QNRX) gave up most of its early gains to trade 1 % higher on Wednesday, after the company said it has received encouraging feedback from the U.S. Food and Drug Administration (FDA) for its lead drug QRX003 to treat Netherton Syndrome, a genetic disorder that results in severe allergies.The FDA indicated that a single Phase 3 trial may be sufficient to support U.S. approval, rather than the usual two studies. The agency also showed openness to alternative trial designs like randomized withdrawal or delayed-start studies, instead of a traditional placebo-controlled Phase 3 trial.<h2 class="st-heading-2">Phase 3 Trial Remains On Track</h2>Following the Type C meeting, Quoin plans to move ahead with its Phase 3 program and remains on track to complete patient enrollment. The company said it could file for approval as early as 2027.“With our established network of U.S. and EU clinical trial sites, we are confident that we will be in a position to initiate our pivotal Phase 3 program and fully complete recruitment this year,” said CEO Michael Myers.This comes just a week after the FDA granted Fast Track designation to QRX003. The drug is currently being tested in two late-stage trials to evaluate safety and effectiveness. QRX003 has already received Orphan Drug status in both the U.S. and Europe.Quoin also&nbsp;submitted an Orphan Drug Designation (ODD) application for&nbsp;QRX003 in Japan and a&nbsp;Breakthrough Medicine Designation with the Saudi Food and Drug Authority earlier this year.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment for <a href="https://stocktwits.com/symbol/QNRX">QNRX</a> flipped to ‘extremely bullish’ from ‘bearish’ a day earlier, amid ‘extremely high’ message volumes.One user said given the company’s potential, the stock has been “beaten down”<stembedurl>https://stocktwits.com/revuelto/message/648496398</stembedurl>The stock has been under heavy selling pressure this year, slumping around 45%.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$3.95
Prev Close	$3.90
Open	$3.95
Dividend Yield	0.00%
50-Day Moving Average	$5.66
Beta	0.64
Avg. Volume	100,575.84
PE Ratio	-0.26

52-Week High	$23.50
52-Week Low	$3.25
Market Capitalization	$7.83M
EPS (Annual)	-$10.63
Price to Book	1.99
Revenue Per Employee	$0.00

Feed

News

Sentiment

Fundamentals

Info

QNRX Fundamentals